Pre-Conference Workshop Day
Tuesday, 13 September 2022
8.30am - 11:00am | Workshop A: Discussing the Use of Non-Viral Gene Delivery as a Therapeutic Modality to the Eye
- Reviewing the conventional approaches of non-viral delivery (microinjection, electroporation, lipofection) - advantages and limitations
- Laser based approach for non-viral targeted delivery-safety and efficacy
- Clinical translation roadmap of image-guided laser-based gene delivery-safety, regulatory path
Subrata Batabyal
Senior Technical Officer
Nanoscope Technologies
Dr. Sanghoon Kim
Project Engineer
Nanoscope Technologies
Gayathri Ramaswam
VP, Drug Discovery & Disease Biology
Intergalactic Therapeutics
11:30am - 2:00pm| Workshop B: Preclinical Advances, Challenges and Tools For Developing Novel Gene
Therapies For Retinal Ganglion Cell Neuroprotection, Regeneration and Repair in Optic Neuropathies
- State of the art on retinal ganglion cell neuroprotection and regeneration
- Challenges remaining for retinal ganglion cell repair in optic neuropathies
- AAV-CRISPR screening in optic nerve crush model for identification of novel gene therapy candidates
Shane Hegarty
Chief Scientific Officer & Co-Founder
AXONIS Therapeutics
2.30pm - 5:00pm | Workshop C: Opportunities & Challenges for Ocular, Systemic, Functional and Structural
Biomarkers for Retina Indications
- What are the challenges in IRD trials?
- Functional and structural end points for IRD, past, present and future
- Physical demonstration of select low vision tests
- Biomarkers in clinical development
Stephen Poor
Director of External Innovation and Translational Biomarkers
Novartis Institutes for BioMedical Research
Maen Obeidat
Executive Director – Therapeutics Area Head, Biomarker Development, Ophthalmology
Novartis Institutes for BioMedical Research
Ramkumar Ramamirtham
Associate Director & Optometrist
Novartis Institutes for BioMedical Research